

Assessment of phytoconstituents and Antidiabetic activity of the Crude extract and Partitioned Fractions of *Maytenus senegalensis* (Lam.) Exell (Celastraceae) root bark

ABSTRACT

Maytenus senegalensis (Lam.) Exell (Celastraceae) (*M. senegalensis*) is a tropical plant used in traditional medicines against cough, pneumonia, tuberculosis, respiratory ailments, sore throat, earache, eye infections, rheumatism, amebic dysentery, stomach ache, malaria, haemorrhoid, infertility and venereal diseases as well as ethnomedicinally used in Nupeland for the management of diabetes. The present study reports the phytoconstituents evaluation as well as antidiabetic activity determination of the root bark extract of *M. senegalensis* on alloxan-induced diabetic rats. Phytoconstituents analysis and characterization of the root bark extract of *M. senegalensis* were determined using standard phytochemical methods and GC-MS analysis respectively. The crude extract was partitioned using different solvents of varying polarities and the fractions obtained were tested for their phytoconstituents. The preliminary phytochemical analysis of *M. senegalensis* root bark indicates the presence of alkaloids, flavonoids, saponins, tannins and steroidal compounds. Anthraquinones was completely absent. The root bark of *Maytenus senegalensis* was extracted by 70% methanol which was then partitioned using four solvents of different polarities. The crude extract and solvent soluble fractions were used to determine the antidiabetic activity against alloxan induced (150 mg/kg body weight) diabetic rats, after oral administration at a dose of 200 mg/kg body weight for two weeks. The result revealed reduction in the elevated blood glucose level by 29.75%. Treatment with the known antidiabetic drug, glibenclamide (5 mg/kg body weight) lowered blood glucose level by 27.03% indicating significant improvement in activity. Results obtained indicate that 70% methanolic fraction (aqueous methanol soluble fraction) has highest and most effective activity. This aqueous methanol fraction was then subjected to column and thin layer chromatography as well as GC-MS analysis. The GC-MS spectrum reveals the presence of seven different compounds which may have contributed to the ethnomedicinal properties of this plant. Scientific research has supported the ethnomedicinal claims that *M. senegalensis* is useful in diabetes management. However, the isolation, purification and characterization as well as mechanism of action of bioactive constituents underlying its curative properties are suggested.

Keywords: Phytoconstituents, *Maytenus senegalensis*, Antidiabetic activity

1. INTRODUCTION

Diabetes mellitus is a metabolic disorder caused by deficiency in production of insulin by the pancreas, or by a loss of glucose homeostasis with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, or insulin action, or both [1]. The central identifying features of diabetes mellitus are hyperglycemia, hypoinsulinemia and dyslipidemia. Diabetes mellitus is globally considered to be a threat in the 21st century [2]. Worldwide, there are different prevalent levels varying from country to country, race and ethnic groups [3]. The number of people with diabetes is increasing in every country. According to WHO projection, the prevalence of diabetes is likely to increase by 35%. Currently there are over 150 million diabetics worldwide and this may double by the year 2030 [4]. Half of people with diabetes are undiagnosed. 4.8 million People died due to diabetes. More than 471 billion USD were spent on healthcare for diabetes. In 2011, 14.7

million adults in the Africa region are estimated to have diabetes, with a regional prevalence of 3.8%. Some of Africa's most populous countries also have the highest number of people with diabetes, with Nigeria having the largest number (3.0 million) in the region. Nigeria with over 250 tribes and different culture and food values show increasing rates of diabetes [5, 6]. The progressive increase in the prevalence rates of diabetes is associated with lifestyle changes. Over 30% of our elite population including decision-makers is diabetic [7]. It is a global problem and number of those affected is increasing day by day. According to the report of Oputa and Chinenye [8], diabetes-related deaths in Nigeria in 2011 accounted for 63 340 people, the number of diabetic cases in Nigeria is expected to increase [5]. Currently, diabetes is controlled by diet, exercise, insulin replacement therapy and by the use of herbal hypoglycemic agents [9]. However, available oral hypoglycemic drugs have serious side effects such as nausea and vomiting, jaundice, and hemolytic anemia, generalized hypersensitivity reactions, dermatological reaction and lactic acidosis. Therefore, searching for effective, low cost and less side effected hypoglycemic agents is important. The plants provide a potential source of hypoglycemic drugs because many plants and plant derived compounds have been used in the treatment of Diabetes mellitus [10-14]. The World Health Organization (WHO) reported in 2001 that the herbal medicine can serve the health need of about 80% of the world's population, especially for millions of people in the vast rural areas of developing countries [15]. Many indigenous plants are major ingredients of traditional medicine [16]. The World Health Organization (WHO) has listed 21,000 plants, which are used for medicinal purposes around the world. Numerous studies have been conducted on traditional usage of plants which are often substantiated by scientific investigation that resulted in the isolation of bioactive compound for direct use in medicine [17].

Experimental evidences have confirmed the hypoglycaemic activity of a number of indigenous African medicinal plants. Following the WHO's recommendation for research on the beneficial uses of medicinal plants in the treatment of diabetes mellitus [18] and the increased demand by patients to use the natural product with antidiabetic activities [19], investigations on hypoglycemic agents from medicinal plants have gained momentum. Medicinal plants are being looked into once again for the treatment of diabetes. Many conventional drugs have been derived from prototypic molecules in medicinal plants. Metformin exemplifies an efficacious oral glucose-lowering agent. Its development was based on the use of *Galega officinalis* to treat diabetes. *Galega officinalis* is rich in guanidine, the hypoglycemic component. Due to the fact that guanidine is too toxic for clinical use, the alkyl biguanides synthalin A and synthalin B were introduced as oral anti-diabetic agents in Europe in the 1920s but were discontinued after insulin became more widely available. However, experience with guanidine and biguanides prompted the development of metformin.

To date, over 400 traditional plant treatments for diabetes have been reported, although only a small number of these have received scientific and medical evaluation to assess their efficacy. The hypoglycemic effect of some herbal extracts has been confirmed in human and animal models of type 2 diabetes. The World Health Organization Expert Committee on diabetes has recommended that traditional medicinal herbs be further investigated. Major hindrance in combination of herbal medicine in modern medical practices is lack of scientific and clinical data proving their efficacy and safety. There is a need for conducting clinical research in herbal drugs, developing simple bioassays for biological standardization, pharmacological and toxicological evaluation, and developing various animal models for toxicity and safety evaluation.

Likewise, it is also important to establish the active component(s) from these plant extracts. Therefore, search for more effective and safer hypoglycaemic agents has continued to be an important area of active research. Medicinal plants contain a variety of chemical substances

and have been reported to possess many useful properties including antidiabetic and antimicrobial activities [14, 20-22]. The medicinal value of these plants lies with these chemical substances that produce a definite physiological action on the human body. The most important of these constituents of plants are terpenes, alkaloids, tannins, flavonoids and phenolic compounds [24]. The bioactivity in *Maytenus* species has been attributed to various groups of secondary metabolites such as triterpenes and several types of alkaloids [24]. The genus *Maytenus* is a rich source of quinonemethide triterpenes and these compounds seem to have a variety of biological activities such as antimicrobial, cytotoxic, antimalarial and veterinary properties [25-30].

World ethnobotanical information about medicinal plants reports that almost 800 plants could be used to control diabetes mellitus [14, 22, 31]. Several investigations have been conducted and many plants have shown to possess antidiabetic potentials and active principles [32-44]. Even though active principles have been isolated from some plants [1, 45-48]; many are yet to be identified. These necessitated the search for new bioactive compounds with proven and effective antidiabetic property from medicinal plants.

Many Nigerian medicinal plants have been found to demonstrate significant antidiabetic activity [49-59]. One of such medicinal plants is *Maytenus senegalensis* which belongs to the Celastraceae family and popularly employed in the management of diabetes and other ailments in Nupeland, North Central Nigeria [60, 61]. *M. senegalensis* is a spike-thorny tall shrub or tree with young branches often spiny which grows up to 15m high, unarmed or with spines up to 7cm long (Figure 1). Its leaves are simple, glabrous, alternate or borne in clusters, greyish-green in colour and with a thick central mid-rib. The plant flowers in October and the flowers appear small in axillary, dioecious, scented peduncle 1-16 mm long, pedicels up to 6 mm long. The fruits are small pink to red capsules globose, 4-5 mm broad and bivalved. Capsule with two compartments each containing a smooth reddish-brown seed chestnut brown; arillode orange [62].



Fig. 1. Showing spike thorny stem, branches with leaves, flowers and

fruits of *Maytenus senegalensis* (Photographed by A. Mann)

M. senegalensis is commonly called spike thorn. Its synonym is *Gymnosporia senegalensis* [63]. It is found widely distributed in tropical and subtropical regions of both Asia and Africa [64]; and often found in Nigeria; among the Nupe speaking people, it is called "Tsukukporikan", "Kpakan", "Ekanshelu" in Nupe [61]; Hausas, called it "Mangaladi", "Namiji Tsada", "Bokaroro", "Kunkushewa"; "Tultulde", "Yare-lesdi" in Fulani; Yorubas call it "Sepolohun" and "Afor-juru", "Yabasi" in Igbo [65]. *M. senegalensis* is extensively used in African ethnomedicine for treating a number of disease conditions which include chest pains, pneumonia, tuberculosis, pulmonary cough, sore throat, earache, healing wounds, ulcer, boils, dyspepsia, aphrodisiac, ocular illnesses, oedema, gastro-intestinal disorders especially dysentery, diarrhoea, pains of teeth, tooth decay, gingivitis, eye infections, rheumatism, infertility, stomach ache, stomatitis, fever, menstrual pain relief, haemorrhoid and venereal diseases such as gonorrhea, syphilis [66-74] and epilepsy [75], aphrodisiac [76]. The roots are mostly used in preparing traditional remedies, for instance it is administered for the treatment of sleeping sickness and stomach ache [77] and snakebites [78]. Its decoctions are widely used in Sudan and other African countries in the traditional medicine to treat malaria and resistant malaria [66, 79], and analgesic and anti-inflammatory activities [80-83].

The *Celastraceae* family is a source of important bioactive secondary metabolites [84-86]. Alkaloid amines such as cathine often occur in this botanical family as also, rarely, benzyloquinolide alkaloid, ephedrine, norephedrine [87]. Celastraceae members are commonly tanniferous, containing anthocyanins, anthocyan, ferula acid sometimes saponiferous, only rarely cyanogenic and without iridoid compound [87]. Bioguided fractionation of the chloroform extract of the root bark of *M. senegalensis* resulted in the isolation and characterization of the dihydro- β -agarofuran sesquiterpenes, triterpenes like betulin and triterpenoid quinonemethides which are of great interest due to their wide range of biological activities [87]. Constituents as β -amyrin, lupane derivatives and quinoid pigments are considered typical of the *Celastraceae* family members. Compounds isolated from the *Maytenus* genus include the ansamacrolide, maytansine, and related macrolides such as normaytansine, maytanprine and maytanbutine. Two of the more well-known chemicals are mayteine and maytansine - alkaloids long documented (since the 1960s) with antitumor activity and which occur in other *Maytenus* plants as well. Other isolated compounds include maytenoic acid and pristimerin [88, 89], spermidine alkaloids (celacinnine and celalocinnine) and nicotinoyl sesquiterpene alkaloids (maytoline and maytolidine) as well as catechin, epicatechin, procyanidins and phenoldienone triterpenoids [90]. *M. senegalensis* leaf was found to contain alkaloids, alkanes and alkanols, terpenes and steroids and phenol compounds [91]; tannins and phenolics were isolated from its stem-bark [92, 93]; while the triterpenes such as β -amyrin, lupenone, maytenoic acid, pristimerin and β -sitosterol were isolated from the root bark [68, 89].

Many biological activities of *M. senegalensis* extracts were confirmed by pharmacological studies. Thus, following the traditional use of the plant in Africa, it was demonstrated that various *in vitro* and *in vivo* pharmacological studies revealed that *M. senegalensis* possess antimicrobial, antidiarrhoeal, anthelmintic, antioxidant, anti-inflammatory and analgesic properties. For instance, leaf, root and stem bark extracts of *M. senegalensis* possess *in vitro* antiplasmodial [66, 94-98], antileishmanial [27, 29, 97], antitrypanosomal [98], and antibacterial activities [68]. Maytenonic acid, isolated from the root-bark of this plant has proved to have antibacterial activity against *B. subtilis*, *E. coli*, *K. pneumoniae* and *S. aureus* [89, 99]. An acetone extract of the aerial parts of this species has been revealed to be active against a sensitive strain of *Mycobacterium tuberculosis* [67]. The anti-inflammatory activity of *M. senegalensis* ethanol extract was determined in Wistar albino rats and it was reported

that the extract exhibited significant anti-inflammatory (120mg/kg), reducing it by 35% [100]. *M. senegalensis* extracts were tested on 3-4 weeks old rats infected with *Schistosoma mansoni* and it was confirmed that acetonic and methanolic extracts are potent antischistosomal component, with efficacy on schistosoma [26]. Furthermore, an antiviral activity, as HIV-1 protease inhibition, was demonstrated for hydrophilic extracts of the stem and for their phenolic constituents [90, 92]. The findings of Mbatchou and Adoum [79] is said to have been in conformity with antibacterial activities reports of Matu and van Staden [68] as well as the ethnomedicinal uses of *Maytenus senegalensis* when the screened extracts of stem-bark inhibited the growth of *Escherichia coli*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Proteus vulgaris* and *Klebsiella pneumonia* which are causative agents of genitourinary tract infections. Screening studies on antitumoral properties of *M. senegalensis* root and stem extracts revealed an *in vitro* cytotoxic activity against carcinoma cells [95, 101] and an *in vivo* antileukemia effect [101]. The bark and leaf extracts of *M. senegalensis* were shown to inhibit cyclo-oxygenase-1, an enzyme responsible for the synthesis of inflammatory mediators, such as prostaglandins and thromboxanes [68]. The analgesic activity has been demonstrated by aqueous extracts of the leaves of *M. senegalensis* with pain inhibition of 72%. In the anti-inflammatory test, the oedema inhibition 3h after carrageenan injection was respectively 64% and 66 % for leaves and roots of *M. senegalensis* [82]. The chloroform extract of roots along with maytenoic acid exhibited highest anti-inflammatory by reducing the oedematous response, with potency similar to indomethacin [89]. Leaf extracts exhibited also significant anti-inflammatory activity at the dose of 120 mg/kg, per os, reducing oedema by 51%. Aqueous extract administered orally in mice was not toxic [82]. However, the ethanol extracts of leaf or stem administered to mice and rats revealed some signs of toxicity [100].

In Nupeland of North Central Nigeria, the root and stem barks of *Maytenus senegalensis* have been reported as being effective and commonly used for the management of diabetes [61]; but this has not been scientifically investigated for the bioactive single agents. Therefore, the present research work is designed to determine the phytoconstituents and antidiabetic activity of the root bark extract of *M. senegalensis* using 70% methanol in alloxan induced diabetic rats and to isolate active principles single compounds responsible for the antidiabetic activity.

2. MATERIAL AND METHODS

2.1 Plant material

The root bark of *Maytenus senegalensis* was collected based on ethnobotanical information from Patishin swasun forest, 5 km along Bida-Busu Road, Niger State, Nigeria. The sample was collected in month of January, 2012. Plant was identified and authenticated by Mr Umar S Gallah, a plant taxonomist at the Department of Biological Sciences, Ahmadu Bello University, Zaria, Nigeria where a voucher specimen with a herbarium number (900199) was deposited.

2.2 Preparation of samples

The root bark of *M. senegalensis* collected from the forest were thoroughly washed with distilled water, air-dried at room temperature under shade and prepared according to methods described by Mann [102]. It was then pulverized into uniform powder manually. The sample was then sieved (40 mesh sizes), weighed, bottled, sealed, labeled and kept in polyethylene bag for analysis.

2.3 Extract preparation

The pulverized *M. senegalensis* root (249 g) was macerated by soaking in 70% methanol (500 mL, 72 h) at room temperature. This was repeated thrice and the resultant extracts were combined and then concentrated *in vacuo* using rotary evaporator ((NYS RD-205D) at 35°C to give the crude methanolic extract. The extract was air-dried, weighed, packed in a glass bottle and labeled as the crude methanol extract of *M. senegalensis* and kept under refrigeration away from light by wrapping with aluminum foil prior to further processing and then used to calculate percentage recovering.

2.4 Qualitative analysis of the crude methanolic extract of *M. senegalensis*

The crude methanolic extract was screened for the presence or absence of secondary metabolites such as alkaloids, steroidal compounds, phenolic compounds, flavonoids, saponins, tannins and anthraquinones using standard procedures [1, 23].

2.5 Partitioning of the crude extract

The crude methanolic extract (69 g) was dissolved in 500 ml of methanol. The resultant solution was partitioned with 250 ml thrice each in order of their increasing polarities (*n*-hexane, chloroform and *n*-butanol) [102]. All the four fractions obtained were filtered one after the other using Whatman No.1 filter paper sheets (Whatman Int. Ltd. Maidstone, England). Each extracts was then concentrated in water bath at 35°C by the evaporation of various solvents from the extracts after which phytochemical screening was conducted on each fraction and the methanolic extract which was having most of the metabolite was taken for further analysis.

2.6 Experimental Animals

Twenty four young male Wister strain albino rats weighing between 95-130 g of both sexes were obtained from Benue State University, Makurdi, Benue State. Before and during the experiment, the rats were allowed free access to standard feed (purchased from Grand Cereal and oil meals Limited, Jos, Plateau State) and water. After randomization of the various groups and before initiation of experiment, the rats were acclimatized to the animal house conditions [42] at the Department of Biochemistry, School of Natural and Applied Science, Federal University of Technology, Minna, Nigeria. Prior to each study, the animals were made to fast for 12-16 h [103]. All the animal experiments were conducted at Biochemistry Laboratory, School of Natural and Applied Sciences, Federal University of Technology, Minna, Nigeria.

2.7 Induction of Experimental Animals

White albino rats were fasted overnight (12-14 h) and their weight and fasting blood glucose level were recorded determined using glucometer (Fine test; Infopia Co Ltd, Korea). They were then made diabetic by a single intraperitoneal injection of alloxan monohydrate (150 mg/kg body weight). Alloxan of 1g was first weighed and then solublized with 10ml distilled water which serves as a stock just prior to injection. Food and water were presented to the animals 30 minutes after administration [42, 104]. Two days after alloxan injection, plasma blood glucose level of each animal was determined and animals with a fasting blood glucose range above 190 mg/dl were included in the study. The blood samples were collected from the tail of the rats.

2.8 *In vitro* Antidiabetic screening of the crude extract

During the course of the experiment, the rats were divided into 4 groups for the evaluation of fasting blood glucose level with four animals in each group.

Groups 1 served as negative (took only the vehicle)

Group 2 served as positive (diabetes) control (diabetic but not treated).

Group 3 took standard drug (glibenclamide, 5mg/kg per day orally) [42].

Groups 4 were treated with extract of *M. senegalensis* (200 mg/kg) in 1ml of DMSO through gavages daily for 2 weeks [105]. Treatment with plant extract started 48 h after alloxan injection. Blood samples were drawn at weekly intervals till the end of the 2 weeks study. Fasting blood glucose levels and body weight measurement of all the rats were recorded on day 1, 7 and 14 during the experimental period [42].

2.9 *In vitro* Antidiabetic activity screening of the Fractions

The rats were divided into four groups for the evaluation of fasting blood glucose level with two animals in each group as thus;

Group 1 was treated with *n*-hexane fraction.

Group 2 was treated with chloroform fraction.

Group 3 was treated with *n*-butanol fraction.

Group 4 was treated with 70% methanol fraction.

Group 5 served as positive control (diabetic but untreated).

Treatment with the fractions started 48 h after induction. Blood samples were drawn at weekly intervals till the end of the study, 2 weeks. Fasting blood glucose levels and body weight measurement of all the rats were recorded on day 1, 7 and 14 during the experimental period [42].

2.10 Data analysis

Data were statistically evaluated by use of one-way ANOVA, followed by post hoc Scheffe's test using version 13 of SPSS software and Microsoft office excel 2003. The values were considered to be significant at $p < 0.05$.

2.11 Column Chromatography of the crude methanol extract

Slurry was prepared by shaking 28.53 g of silica gel (particle size 0.040-0.063 nm; 70-230 mesh, Merck) with 200 ml of hexane and then packed using wet method in a column (3 x 30cm). The silica gel was first activated in the oven for 2 h at 105°C. One gramme (1g) of the extract was re-dissolved in 50 ml of acetone and 20 g of the activated silica gel was used to absorb the dissolved extract. The dissolved extract was then kept under fan to dry. The dried absorbent (silica gel) with the sample embedded was then introduced to the top of the packed column and some quantities of silica gel were added on top followed by boiling chips. The above prepared column was then eluted using gradient mixtures of *n*-hexane-EtOAc (100:0 → 95:5 → 20:80 → 0:100) and MeOH. Eluents were collected in 50 ml and were then monitored by TLC behaviour [102].

2.12 Thin Layer Chromatography Analysis of the eluents

The recovered fractions were dissolved in the appropriate solvent. A line was drawn 2 or 3 cm from the base of each TLC plate (to serve as origin) for spotting. Adopting one dimensional and ascending technique, a fine bore glass capillary tube was used to apply a spot of each of the fraction on the pre-coated TLC plates. Similarly other eluents collected from column chromatography were treated in the same manner. Various solvent systems were tried in order to get good separation or resolution of the constituent spots. Finally the solvent system EtOAc-MeOH, 4:1 that gave the best separation or resolution was adopted and then introduced into the tank and the lid placed until the tank is saturated with the vapour of the solvent system. The plates were then carefully introduced into the tank with the origin about 1.5- 2.0 cm above the solvent system and allowed to stand for a few minutes. The plates were then removed and allowed to dry under the fan. The developed chromatograms were observed for separation under ultraviolet light (long, 254 nm) and (short, 366 nm). Similarly, the plates were also observed under iodine vapour. The *R_f* values of the spots were then measured [106].

2.13 GC/MS analysis of the extract

GC-MS analysis was carried out on a Shimadzu (Kyoto, Japan) GC-MS model QP 2010 at National Research Institute for Chemical Technology, Zaria, according to the EN 14103 standard method [107, 108]. The GC column oven temperature (70°C), injecting temperature (250°C), flow control mode (linear velocity), total flow (40.8 ml/min) column flow (1.80 ml/min), pressure (116.9 kpa), linear velocity (49.2 cm/sec) and purge flow (3.0 ml/min) were employed for this analysis. A sample volume of 8.0 µL was injected using split mode (split ratio of 20.0). The peak area, that is, the % amount of every component was calculated by comparing its average peak area to the total areas. Software was used to handle mass spectra and chromatogram.

2.14 Identification of components from the extract

Interpretation of mass spectrum GC-MS was conducted by comparing the database peaks of National Institute Standard and technology (NIST) library with those reported in literature, the mass spectra of the peaks with literature data [109]. The spectrum of the unknown component was compared with the spectrum of the known components stored in the NIST library. Component relative percentages were calculated based on GC peak areas without using correction factors. The Name, Molecular weight and structure of the components of the test materials were ascertained.

3. RESULTS AND DISCUSSION

3.1 Preliminary Phytochemical Screening

Phytochemical screening was done using colour forming and precipitating chemical reagents on both the crude and fractionated extract to generate preliminary data on the constituents of the plant extracts. The results obtained from the tests were summarized in tables 1 and 4 for both crude and fractionated extracts. The chemical tests revealed the presence or absence of major secondary metabolites such as alkaloids, steroidal compounds, phenolic compounds, saponins, etc in the extracts. The result indicated the presences of flavonoids, alkaloids, saponins and phenolic compounds. Previous study indicated the presence of secondary metabolites like flavonoids, alkaloids, saponins [26]. Plants with hypoglycemic and antihyperglycemic activities may contain one or more chemical constituents. Classes of chemical compounds isolated from plants including alkaloids (vindoline), flavonoids (epicatechin), tannin (catechin), etc are documented to have the potential to decrease the blood glucose level [103, 110,111]. Thus, the significant antidiabetic effect of both the crude and fractionated extract could be due to the possible presence of the aforementioned constituents in the part of the plant used in this particular study, which could act synergistically or independently enhancing the activity.

Table 1. Phytochemical analysis of the Crude extract and aqueous Methanol fraction of *M. senegalensis*

Phytoconstituents	Chemical Test	Crude Methanol Extract	Aqueous Methanol Fraction
Alkaloids	Dragendorff's reagent	+	+
	Mayer's reagent	+	+
Steroidal Compounds	Acetic anhydride and Conc. Sulphuric acid	+	+
	Chloroform and Conc. Sulphuric acid	+	+
Phenolic Compounds	Ferric chloride and Potassium Ferrocyanide	+	+
Flavonoids	Ammoniacal silver nitrate	+	+
Saponins	Froth	+	+
Tannins	Ferric chloride	-	-
Anthraquinones	Borntrager's	-	-

Key: + → positive, - → negative

3.2 Partitioning of the crude extract

The crude extract dissolved in methanol was partitioned using three different solvents (*n*-hexane, chloroform and *n*-butanol) in order of their increasing polarities and the fractions obtained is shown in table 2 below.

Table 2. Fractions obtained during the partitioning

Fraction	Weight (g)
<i>N</i> -Hexane	2.80
Chloroform	6.90
<i>N</i> -Butanol	12.13
Aqueous Methanol Fraction	16.40

3.3 Column Chromatography analysis

The eluents obtained from the column using gradient mixtures of *n*-hexane-ethylacetate and ethylacetate-methanol gave series of fractions which were obtained which were monitored by TLC behavior. Based on the TLC analysis of the fractions, some of the fractions were pooled together as follows: F₂₃, F₃₃, F₄₃, F₅₀, F₅₇, F₅₈, F₆₃, F₆₅, F₇₁, F₇₅, F₈₁, and F₈₄. The R_f values ranges between 0.2-0.8. Most spots are of lower R_f values indicating that most of the component are polar. F₂₃ and F₅₀ show three spots indicating that there are three likely components in each fraction. The spot(s) of each fraction and their corresponding R_f values are shown in Table 3.

Table 3. Pooled fractions after TLC analysis

Fractions	Spots	Rf Values
F ₁₋₂₃	3	0.3, 0.4, 0.5
F ₂₄₋₃₃	1	0.3
F ₃₄₋₄₃	1	0.4
F ₄₄₋₅₀	3	0.5, 0.6, 0.7
F ₅₁₋₅₇	2	0.5, 0.6
F ₅₈₋₆₂	2	0.4, 0.6
F ₆₃₋₆₄	1	0.5
F ₆₅₋₇₀	1	0.3
F ₇₁₋₇₄	1	0.3
F ₇₅₋₈₀	2	0.6, 0.8
F ₈₁₋₈₃	1	0.5
F ₈₄	2	0.4, 0.6

3.4 Combination of the fractions from the column chromatography

The fractions were combined based on their TLC behaviours of similarities in Rf values of the spots and then were so grouped as follows:

F₁₋₂₃ (F₂₃)
 F₃₄₋₄₃ (F₄₃)
 F₄₄₋₅₀ (F₅₀)
 F_{24-33, 65-70, 71-74} (F₇₄)
 F_{63-64, 81-83} (F₈₃)
 F_{58-62, 84} (F₈₄)

3.5 Phytochemical analysis of the TLC fractions

Phytochemical analysis was then carried out on the six fractions and the results were obtained as presented in Table 4.

Table 4. Phytochemical analysis of the TLC combined subfractions


Phytoconstituents	Subfractions					
	F ₂₃	F ₄₃	F ₅₀	F ₇₄	F ₈₃	F ₈₄
Alkaloids	-	+	-	-	-	-
Steroids	-	-	-	-	-	-
Flavonoids	+	+	+	+	+	+
Saponins	-	+	+	+	+	-
Phenolics	-	-	-	-	-	-

Key: + → Positive, - → Negative

3.6 Body weight

The change in the body weight of control and experimental groups of rats treated with *M. senegalensis* is shown in Figure 2. Alloxan-induced (150 mg/kg body weight) rats showed loss in body weight (from 1.10% to 3.39%), which was reversed by oral administration of crude extract and standard drug. The body weight of the normal control rats (negative control), which took the vehicle only, did not show any significant difference, i.e. 0.14% change on the 14th day. However, the body weight of diabetic untreated rats (positive control) showed a 3.37% decrease after two weeks. Significant body weight improvement was observed starting from day 1 in diabetic rats treated with both the crude extracts and standard drug. The effect was a bit pronounced in case of the crude extract treated rats with 1.95% increment on the 7th day of treatment and on the 14th day, the body weight increased up to 3.05% (from 129.13 to 133.20) during the experimental period. In case of standard drug the body weight increased from 114.68 to 115.20 equivalent to 1.45% increment, and on the 14th day the weight improved to 116.21 (2.53%). More so, the ANOVA was also conducted and the result which shows that $F(3,44) = 337.230$; $P < 0.05$ indicates that there

414 is a high significant difference in change in mean body weights of Normal Control and
 415 Alloxan- Induced Diabetic Rats as shown in the table 4 below.
 416
 417



418
 419
 420 **Fig. 2. Effect of Crude extract of *M. senegalensis* on Body weight in Rats**
 421

422 The fasting mean blood glucose level values before and after treatment for two weeks in all
 423 the four groups are presented in Figure 3 below. Diabetic control mice were compared with
 424 normal control mice and diabetic mice that were treated with the crude extracts were
 425 compared with diabetic untreated mice. The fasting mean blood glucose levels did not show
 426 a significant difference in normal control (negative control) rats. In the case of diabetic
 427 untreated (positive control) rats, the fasting mean blood glucose level showed a statistically
 428 significant ($p < 0.05$) increase as compared to the normal control rats after two weeks during
 429 the experimental period. On treatment with crude extract, the fasting mean blood glucose
 430 levels on day 7, i.e. 292.00 mg/dl reduced to 251.25mg/dl. This reduction accounts
 431 for 13.96%. On 14th day, the fasting BGL reduced to 176.50 which is equivalent to 29.75%.
 432 The fasting mean blood glucose level of diabetic rats treated with glibenclamide showed a
 433 reduction of 12.60% after 7 days, i.e. from 304.65 to 266.25mg/dl which further reduced by
 434 27.03% on 14th day (from 266.26 to 194.25mg/dl) as compared with diabetic control (positive
 435 control) mice. Conversely, fasting blood glucose of alloxan – induced diabetes rats in
 436 standard, diabetic and extract controls are found not to be statistically different from one
 437 another other.
 438
 439




Fig. 3. Effect of Crude extract of *M. senegalensis* on FBS in Rats

3.7 Effects of fractions on fasting mean blood glucose level (FBS)

On treatment of diabetic rats with chloroform fraction, the fasting mean BGL reduced from 218.23 to 207.60 after 7 days which account for about 4.87% and on the 14th day, the fasting BGL showed no significant different. Treatment with hexane fraction brought about 9.15% reduction in fasting BGL i.e. from 215.84 to 195.5 after 7 days and on 14th day the BGL reduced to 189.50 which shows reduction of 3.07%. Methanolic fraction gave a reduction of 16.94% in fasting BGL i.e. from 231.17 to 192.00 on 7th day, and on 14th day, the percentage reduction increased to 36.67% i.e. from 192.00 to 121.60. Butanol fraction reduced fasting mean BGL from 263.40 to 228.00 (13.44%) on 7th day and on 14th day to 211.00 (7.46%). There was no reduction in fasting mean BGL of the diabetic untreated rats (positive control). From the graph (Figure 4), it can therefore be inferred that the methanolic fraction shows the highest activity; hence phytochemical screening was conducted and the result obtained is represented in the Figure 4 below.




Fig.4. Effects of various solvent soluble fractions of *M. senegalensis* on FBS

461

462

3.8 GC-MS for *M. senegalensis* combined subfraction (F₄₃)

463

The combined subfractions (F₄₃) of *M. senegalensis* on phytochemical screening were observed to have flavonoids, saponins, and trace amount of alkaloids was then taken for GC-MS analysis. The compounds present in the combined subfractions (F₄₃) were identified by GC-MS as shown in Figure 6. The peaks with their peak area %, molecular formula, molecular mass and individual fragmentation patterns observed for each of the suggested compounds namely: hexadecanoic acid, 9-octadecenoic acid (Z), 12-hydroxy-9-octadecenoic acid (Z), methyl-1-cyclopentene-1-carboxylate, 12-hydroxy-9-octadecenoic acid, methyl ester (Z); 1, 1-dimethoxyacetone and 13-hexyloxacyclotridec-10-en-2-one are shown in Table 5.

464

465

466


467

468

469

470

471



472

473

Fig. 5. GC-MS chromatogram for *M. senegalensis* combined subfraction (F₄₃)

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496
497
498

Table 5. Parameters deduced from GC-MS spectrum of *M. senegalensis* combined subfraction (F₄₃)

Line No	IUPAC Name	Molecular Formula	Molar Mass	R.T(S)	% Area	Fragmentation Peaks
1	1,1-Dimethoxy acetone	C ₅ H ₁₀ O ₃	118	3.51	20.75	55, 57, (75), 87, 118
2	Methyl-1-cyclopentene-1-carboxylate	C ₇ H ₁₀ O ₂	126	5.60	2.73	51, (67), 95, 111, 126
3	Hexadecanoic acid	C ₁₆ H ₃₂ O ₂	256	21.18	2.85	55, (73), 85, 98, 115, 129, 149, 213, 256
4	13-Hexyloxa cyclo tridec-10-en-2-one	C ₁₈ H ₃₂ O ₂	280	22.69	11.81	55, 67, 81, 96, (98), 123, 137, 166, 280
5	9-Octadecenoic acid (Z)	C ₁₈ H ₃₄ O ₂	282	23.60	10.50	(55), 69, 83, 97, 112, 264
6	12-Hydroxy-9-octadecenoic acid, methyl ester (Z)	C ₁₉ H ₃₆ O ₃	312	24.94	38.05	(55), 69, 74, 96, 124, 137, 148, 166, 195, 263, 294
7	12-Hydroxy-9-octadecenoic acid (Z)	C ₁₈ H ₃₄ O ₃	298	25.46	13.31	(55), 69, 83, 97, 124, 137, 148, 166

499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521

3.9 Phytoconstituent identification of *M. senegalensis* combined subfraction (F₄₃) by GC-MS

Based on the results of antidiabetic activity, the methanolic fraction of *M. senegalensis* was fractionated using column chromatography to give six combined subfractions namely: (F₂₃), (F₄₃), (F₅₀), (F₇₄) (F₈₃) and (F₈₄). Similarly, based on the results of the phytochemical analysis of the six combined subfractions of *M. senegalensis* above, only combined subfractions (F₄₃) was analysed using GC-MS spectrometer [104]. In present study, seven different compounds were identified with the help of standard library search software and the constituents identified belong to the class of saturated and unsaturated fatty acids, fatty acid esters and ketones family (Table 5). The GC-MS spectrum of the combined fractions (F₄₃) of *M. senegalensis* after fractionation using column chromatography in conformity with TLC analysis revealed the presence of many components namely: hexadecanoic acid, 9-octadecenoic acid (Z), 12-hydroxy-9-octadecenoic acid (Z), methyl-1-cyclopentene-1-carboxylate, 12-hydroxy-9-octadecenoic acid, methyl ester (Z); 1, 1-dimethoxyacetone and 13-hexyloxacyclotridec-10-en-2-one as shown in Table 5. The major peaks are fatty acids such as hexadecanoic acid, 9-octadecenoic acid (Z) and 12-hydroxy-9-octadecenoic acid (Z) as well as fatty acid derivatives such as methyl-1-cyclopentene-1-carboxylate and 12-hydroxy-9-octadecenoic acid, methyl ester (Z). The fraction also contained 1, 1-dimethoxyacetone and 13-hexyloxacyclotridec-10-en-2-one. The presence of these fatty acids in a considerable amount might serve to recognize the potential pharmacological importance of this plant.

4. CONCLUSION

Phytochemical investigation of *Maytenus senegalensis* revealed the presence of flavonoids, saponins and alkaloids, while the GC-MS analysis identified compound such as 1, 1-dimethoxyacetone, 13-hexyloxacyclo-tridec-10-ene and 12-hydroxy-9-octadecenoic acid, methyl ester (Z) as the major constituents present. These metabolites are chemical substances known to possess potentials in the management of diabetes. Compounds belonging to these chemical groups are known to be bioactive for the management of diabetes. A significant antidiabetic activity was observed with the root bark methanolic extract of *M. senegalensis* having the highest activity of 36.67% reduction of blood glucose level in rats. Their classes of compounds were earlier associated with antidiabetic, antimalarial and analgesic activities. This is therefore in support of the traditional use of this plant in Nupe ethnomedicine for management of diabetes in humans. Further studies are required to identify, isolate and spectrally elucidate the active components present in the root bark extract of *M. senegalensis* using NMR analysis.

REFERENCES

1. Tadesse B. Antidiabetic activity and phytochemical screening of crude extracts of *Stevia rebaudiana* and *Ajuga remota* benth grown in Ethiopia on alloxan induced diabetic mice: M.Sc thesis, Addis Ababa University, Ethiopia, pp 13–16; 2008.
2. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. *Nature*. 2001; 414: 782–787.
3. World Health Organization. Diabetes mellitus report of a WHO study group on diabetes mellitus. Geneva: WHO; (WHO Technical Report, pp 727; 1985).
4. Nyenwe EA, Odia OJ, Ihekwa AE, Ojule A, Babatunde S. Type 2 diabetes in adult Nigerians: a study of its prevalence and risk factors in Port Harcourt, Nigeria. *Diabetes Res Clin Pract*. 2003; 62(3):177–185.
5. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes, estimates for the year 2000 and projections for 2030. *Diabetes Care*. 2004; 27: 1047–1053.
6. Sarah W, Gojka R, Anders G, Richard S, Hilary K. Global prevalence of diabetes. *Diabetes Care*. 2004; 27: 1047–1053.
7. Colagiuri RN, Colagiuri S, Yach D and Pramming S. The answer to diabetes prevention: Science, surgery, service delivery, or social policy: *Amer J Public Hlth*. 2006; 96:1562–1569.
8. Oputa RN, Chinenye S. Diabetes mellitus: a global epidemic with potential solutions. *Afri J Diabetes Med*. 2012; 20(2): 33–35.
9. Day C. Traditional plants treatments for diabetes mellitus: pharmaceutical foods. *Brit J Nutr*. 1998; 80: 5–6.
10. Agosta WC. Medicines and Drugs from Plants. *J Chem Edu*. 1997; 74(7): 857.
11. Gupta R, Bajpai KG, Johri S, Saxena AM. An Overview of Indian novel Traditional Medicinal Plants with Antidiabetic Potentials. *Afri J Trad CAM*. 2008; 5(1): 1–17.
12. Jung M, Park M, Lee HC, Kang Y-H, Kang ES, Kim SK. Antidiabetic Agents from Medicinal Plants. *Current Med Chem*. 2006; 13(10): 1203–1218.
13. Li WL, Zheng HC, Bukuru J, De-Kimpe N. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. *J Ethnopharmacol*. 2006; 92: 1–21.
14. Mukherjee PK, Maiti K, Mukherjee K, Houghton PJ. Leads from Indian medicinal plants with hypoglycemic potentials. *J Ethnopharmacol*. 2006; 106: 1–28.
15. World Health Organization (2001). General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine, WHO, Geneva p.1; 2001.

- 575 16. World Health Organization. Diabetes Prevention and Control: A strategy for the WHO
576 African Region: Report of the Regional Director: Fifty-seventh Session, Brazzaville,
577 Republic of Congo. 27–31; 2007.
- 578 17. Castellanos GRJ, Prieto JM, Heinrich M. Red Lapacho (*Tabebuia impetiginosa*)-A
579 global ethnopharmacological commodity. J Ethnopharmacol. 2009; 121: 1–13.
- 580 18. World Health Organization. WHO traditional medicine strategy 2002–2005. WHO
581 Publications. 1–6; 2002.
- 582 19. Tiwari AK, Rao JM. Diabetes mellitus and multiple therapeutic approaches of
583 phytochemicals: Present status and future prospects. Curr Sci. 2002; 83: 30–38.
- 584 20. Cowan MM. Plant Products as Antimicrobial Agents. Clin Microbiol Rev. 1999; 12(4):
585 564–582.
- 586 21. Kudi AC, Umoh JU, Edvie LO, Gefu J. Screening of some Nigerian medicinal plants
587 for antibacterial activity. J Ethnopharmacol. 1998; 67: 225–238.
- 588 22. Marles RJ, Farnsworth NR. Antidiabetic plants and their active constituents.
589 Phytomedicine. 1995; 2:137–189.
- 590 23. Hymete A. Phytochemical investigation of the fruit of *Lagenaria breviflora* Robert. MSc
591 thesis, Obafemi Awolowo University, Ile-ife, Nigeria, pp 54–67; 1986.
- 592 24. Hutchings A, Scott A, Lewis G, Cunningham A. Zulu medicinal plants: An inventory.
593 Pinetown: University of Natal Press; 1996.
- 594 25. Ahmed AS, McGaw LJ, Eloff JN. Evaluation of pharmacological activities, cytotoxicity
595 and phenolic composition of four *Maytenus* species used in southern African
596 traditional medicine to treat intestinal infections and diarrhoeal diseases. BMC
597 Complement Altern Med. 2013; 13:100. <http://www.biomedcentral.com/1472-6882/13/100>.
598 6882/13/100.
- 599 26. Domo GA, Kela SL. The efficacy of *Maytenus senegalensis* (L) extracts on
600 experimentally infected rats with *Schistosoma mansoni*. Internat J Biomed Hlth Sci.
601 2009; 5(4): 64–71.
- 602 27. El-Tahir A, Ibrahim AM, Satti GM, Theander TG, Kharazmi A, Khalid SA. The potential
603 antileishmanial activity of some Sudanese medicinal plants. Phytother Res. 1998; 12:
604 576–579.
- 605 28. Khalid SA, Friedrichsen GM, Kharazmi A, Theander TG, Olsen CE, Christensen SB.
606 Limonoids from *Khaya senegalensis*. Phytochemistry, 1998; 49: 1769–1772.
- 607 29. Khalid SA, Friedrichsen G, Christensen SB, El-Tahir A, Satti GM. Isolation and
608 characterization of pristimerin as the antiplasmodial and antileishmanial agent of
609 *Maytenus senegalensis* (Lam.) Exell. ARKIVOC. 2007; 9: 129–134.
- 610 30. Koné WM, Atindehou KK. Ethnobotanical inventory of medicinal plants used in
611 traditional veterinary medicine in Northern Côte d'Ivoire (West Africa). S Afri J Bot.
612 2008; 74: 76–84.
- 613 31. Udayakumar R, Kasthuriengan S, Vasudevan A, Mariashibu TS, Rayan JJ, Choi CW,
614 Ganapathi A, Kim SC. Antioxidant effect of dietary supplement *Withania somnifera* L.
615 reduce blood glucose levels in alloxan-induced diabetic rats. Plant Foods Hum Nutr.
616 2010; 65: 91–98.
- 617 32. Andrade-Cetto A, Heinrich M. Mexican plants with hypoglycaemic effect used in the
618 treatment of diabetes. J Ethnopharmacol. 2005; 99(3): 325–348.
- 619 33. Chattopadhyay RR. A comparative evaluation of some blood sugar lowering agents
620 of plant origin. J Ethnopharmacol. 1999; 67: 367–372.
- 621 34. Edem DO. Hypoglycemic effects of ethanolic extract of Alligator pear seed (*Persea
622 americana* Mill) in rats. Eu J Sci Res. 2009; 33: 669–678.
- 623 35. Gbolade AA. Inventory of antidiabetic plants in selected districts of Lagos State,
624 Nigeria. J Ethnopharmacol. 2009; 121: 135–139.
- 625 36. Gidado A, Ameh DA, Atawodi SE. Effect of *Nauclea latifolia* leaves aqueous extracts
626 on blood glucose levels of normal and alloxan-induced diabetic rats. Afri J Biotechnol.
627 2005; 5(4): 91–93.

- 628 37. Grover JK, Yadav S, Vats V. Medicinal plants of India with anti-diabetic potential. J
629 Ethnopharmacol. 2000; 81: 81–100.
- 630 38. Iwu MM, Okunji CO, Ohiaeri GO, Akah P, Corley D, Tempesta MS. Hypoglycaemic
631 activity of dioscoretine from tubers of *Dioscorea dumetorum* in normal and alloxan
632 diabetic rabbits. Planta Med. 1990; 56: 264–267.
- 633 39. Olutimeyin SO, Uguru MO, Ogbonna A. Antimicrobial and hypoglycemic effects of
634 *Momordica balsamina* Linn. J Nat Prod. 2008; 1: 03–09.
- 635 40. Momoh S, Yusuf OW, Adamu MM, Agwu COC, Atanu FO. Evaluation of the
636 Phytochemical Composition and Hypoglycaemic Activity of Methanolic Leaves Extract
637 of *Costu safer* in Albino Rats. Brit J Pharmacol Res. 2011; 1(1): 1–8.
- 638 41. Mohammed B, Abderrahim Z, Hassane M, Abdelhafid T, Abdelkhaleq L. Medicinal
639 plants with potential antidiabetic activity – A review of ten years of herbal medicine
640 research (1990-2000). Internat J Diabetes Metabolism, 2006; 14: 1–25.
- 641 42. Nagappa AN, Thakurdesai PA, Rao NV, Singh J. Antidiabetic activity of *Terminalia*
642 *catappa* Linn fruits. J Ethnopharmacol. 2003; 88: 45–50.
- 643 43. Rahman AU, Zaman K. Medicinal plants with hypoglycaemic activity. J
644 Ethnopharmacol. 1989; 26: 1–33.
- 645 44. Zibula SMX , Ojewole JAO. Hypoglycemic effects of *Hypoxis hemerocallidea* 'African
646 potato' methanolic extract in rats. Med J and Islamic Acad Sci. 2000; 13: 75–78.
- 647 45. Ivorra MD, Paya M and Villa A (1988). Hypoglycaemic and insulin Release Effect of
648 Tormentric acid: A New hypoglycaemic natural product. Planta Med. 54: 282–286.
- 649 46. Latha M, Pari L, Ramkumar KM, Rajaguru P, Suresh T, Dhanabal T, Sitasawad S,
650 Bhonde R. Antidiabetic effects of scoparic acid D isolated from *Scoparia dulcis* in rats
651 with streptozotocin-induced diabetes. Nat Prod Res. 2009; 1–13.
- 652 47. Ribnicky DM, Poulev A, Watford M, Cefalu WT, Raskin I. Antihyperglycemic activity of
653 Tarralin, an ethanolic extract of *Artemisia dracunculus* L. Phytomedicine. 2006; 13:
654 550–557.
- 655 48. Upendra Rao M, Sreenivasulu M, Chengaiah B, Jaganmohan Reddy K,
656 Madhusudhana Chetty C. Herbal Medicines for Diabetes Mellitus: A Review. Internat J
657 PharmTech Res. 2010; 2(3): 1883–1892.
- 658 49. Aguiyi JC, Obi CI, Gang SS, Igweh AC. Hypoglycaemic activity of *Ocimum*
659 *gratissimum* in rats. Fitoterapia. 2000; 71: 444–446.
- 660 50. Akah PA, Okafor CL. Blood sugar lowering effect of *Vernonia amygdalina* (Del.) in an
661 experimental rabbit model. Phytother Res.1992; 6: 171–173.
- 662 51. Fred-Jaiyesimi AA. *In vitro* and *in vivo* Antidiabetic activity of *Parkia biglobosa* (Jacq)
663 Benth and *Spondias mombin* Linn. PhD Thesis. University of Ibadan. Nigeria; 2007.
- 664 52. Fred-Jaiyesimi AA and Abo K. Antidiabetic activity of *Gladiolus psittascinus* in Alloxan
665 induced diabetic rats. Afri J Trad CAM. 2008; 5(2): 154–157.
- 666 53. Gbolade AA, Ekor MN, Akinlolu AA, Ayoola MD. Antidiabetic activity of stem bark
667 ethanolic extracts of *Spondias mombin* on alloxan-induced diabetic rats. J Pharm Res.
668 2008; 7: 83–86.
- 669 54. Iwu MM. Antidiabetic properties of *Beridelia furruginea* leaves. Planta Med. 1980; 39:
670 247.
- 671 55. Saidu A N, Mann A, Onuegbu CD. Phytochemical Screening and Hypoglycemic effect
672 of aqueous *Blighia sapida* Root bark extract on Normoglycemic albino rats. Brit J
673 Pharm Res. 2012; 2(2): 89–97.
- 674 56. Ojewole JAO. Laboratory evaluation of the hypoglycemic effect of *Anacardium*
675 *occidentale* Linn (Anacardiaceae) stem-bark extracts in rats. Methods Find in Exper
676 Clin Pharmacol. 2003; 25: 199–204.
- 677 57. Ojewole JAO. Antinociceptive, anti-inflammatory and antidiabetic effects of
678 *Bryophyllum pinnatum* (Crassulaceae) leaf aqueous extract. J Ethnopharmacol. 2005;
679 99: 13–19.

- 680 58. Ojewole JAO. Analgesic, anti-inflammatory and hypoglycaemic effects of ethanol
681 extract of *Zingiber officinale* (Roscoe) rhizomes (Zingiberaceae) in mice and rats.
682 Phytother Res. 2006; 20: 764–772.
- 683 59. Osadebe PO, Okide GB, Akabogu IC. Study on anti-diabetic activities of crude
684 methanolic extracts of *Loranthus micranthus* (Linn.) sourced from five different host
685 trees. J Ethnopharmacol. 2004; 95:133–138.
- 686 60. da Silva G, Serrano R, Silva O. *Maytenus heterophylla* and *Maytenus senegalensis*,
687 two traditional herbal medicines. J Nat Sci Bio Med. 2011; 2: 59–65.
- 688 61. Mann A, Gbate M, Nda-Umar A. Medicinal and Economic plants of Nupeland. Jube-
689 Evans books and publications, Bida, Niger State, Nigeria, 276pp; 2003.
- 690 62. Burkill HM. The Useful plants of West Tropical Africa. 2. Vol. 4. Royal Botanic
691 Gardens, Kew; 1997.
- 692 63. Vuorela P, Leinonen M, Tammela P, Rauha JP, Wennbrge T. Natural product in the
693 process of finding new drug candidate: Current Med Chem. 2004; 11: 1375–89.
- 694 64. Kokwaro JO. Medicinal plants of East Africa. East Africa Literature Bureau. Kampala
695 Nairobi Kenya; 1976.
- 696 65. Burkill HM. The useful plants of west tropical Africa, Vol 1; 1985.
- 697 66. Johanne B, Habib G, Patrick D. *In vitro* antiplasmodial activity of plants used in Benin
698 as traditional medicine to cure malaria J Ethnopharmacol. 2009; 122: 439–444.
- 699 67. Lall N, Meyer JM. *In vitro* inhibition of drug-resistant and drug sensitive strains of
700 *Mycobacterium tuberculosis* by ethnobotanically selected South African plants. J
701 Ethnopharmacol. 1999; 66: 347–54.
- 702 68. Matu EN, van Staden J. Antibacterial and anti-inflammatory activity of some plants
703 used for medical purposes in Kenya. J Ethnopharmacol. 2003; 87: 35–41.
- 704 69. Okine LKN, Nyarko AK, Osei-Kwabenam N, Oppongm IV, Barnes F, Ofosuhene M.
705 The antidiabetic activity of the herbal preparation ADD-199 in mice: a comparative
706 study with two oral hypoglycaemic or relating to hypoglycemia; "hypoglycemic agents"
707 hypoglycemic drugs. J Ethnopharmacol. 2005; 97: 31–38.
- 708 70. Suzana A, Hall JB, Makonda FBS, Romanus CI. Medicinal Resources of the Miombo
709 Woodlands of Urumwa, Tanzania: Plants its Uses. J Med Plants Res. 2011; 5(27):
710 6352–6372.
- 711 71. Tchacondo T, Simplice DK, Komlan B, Amegninou A, Kawiou O, Kokou TA, Mensavi
712 G, Comlan D. Herbal remedies and their adverse effects in Tem Tribe Traditional
713 medicine in Togo. Afri J Trad Altern Med. 2011; 8(1): 45–60.
- 714 72. Van Wyk B-E, Van Oudtshoorn B, Gericke N. Medicinal Plants of South Africa, 2nd
715 Edition, Briza Publications, Pretoria; 2002.
- 716 73. Neuwinger HD. African Traditional Medicine Adictionary of Plant Use and Applications,
717 Medpharm Scientific Publishers Stuttgart; 2000.
- 718 74. Watt JM, Breyer-Brandwijk MG. The medicinal and poisonous plants of southern and
719 eastern Africa. 2nd Edition, E. & S. Livingstone Ltd., Edinburgh and London; 1962.
- 720 75. Gelfand M, Mavi S, Drummond RB, Ndemera B. The Traditional Medical Practitioner
721 in Zimbabwe. Harare, Mambo Press; 1985.
- 722 76. Coates Palgrave K. Trees of Southern Africa. Cape Town, Struik; 1977.
- 723 77. Iwu MM. Handbook of African Medicinal Plants. CRC Press, INC. pp 252–253; 1993.
- 724 78. Jansen PC, Mendes O. Plantas medicinais: Seu Uso Tradicional em Moçambique.
725 Maputo: Imprensa do Partido; 1991.
- 726 79. Mbatchou VC, Adoum OM. Growth Inhibitory Effects of Solvent Extracts of Selected
727 Plants on β -Lactamase Producing Bacteria. Pak J Nutr. 2010; 9(4): 362–367.
- 728 80. Sanogo R, Diallo D. Study of three plants traditionally used in Mali in the treatment of
729 dysmenorrhoea (I): Ethnobotanical information on *Maytenus senegalensis*,
730 *Stereospermum kunthianum* and *Trichilia emetica*. GA Conference. Florence, 2005.
- 731 81. Sanogo R. Medicinal plants traditionally used in Mali for dysmenorrhea. Afri J Tradit
732 Complement Altern Med. 2011; 8(S): 90–96.

- 733 82. Sanogo R, Maiga A, Diallo D. Activités analgesique et anti-inflammatoire des extraits
734 de *Maytenus senegalensis*, *Stereospermum kunthianum* et *Trichilia emetica* utilisées
735 dans le traitement traditionnel des dysmenorrhées au Mali. Pharm Méd Trad Afri.
736 2006; XIV: 123–136.
- 737 83. Sanogo R. Analgesic and anti-inflammatory activities of the aqueous extracts of
738 *Maytenus senegalensis*, *Stereospermum kunthianum* and *Trichilia emetica* used in the
739 treatment of dysmenorrhoea in Mali. The 12th Symposium of the Natural Product
740 Research Network for Eastern and Central Africa (NAPRECA) July 22–26, 2007,
741 Kampala, Uganda; 2007.
- 742 84. Dos Santos VAFFM, Leite KM, da Costa Siqueira M, Regasini LO, Martinez I,
743 Nogueira CT, Galuppo MK, Stolf BS, Pereira AMS, Cicarelli RMB, Furlan M,
744 Graminha MAS. Antiprotozoal activity of quinonemethide triterpenes from *Maytenus*
745 *ilicifolia* (Celastraceae). Molecules. 2013; 18(1): 1053–1062.
- 746 85. Muhammad I, El Sayed KA, Mossa JS, Al-Said MS, El-Feraly FS, Clark AM, Hufford
747 CD, Oh S, Mayer A M. Bioactive 12-oleanene triterpene and secotriterpene acids from
748 *Maytenus undata*. J Nat Prod. 2000; 63(5): 605–610.
- 749 86. Serrano R, Gomes ET, Silva O. Botanical characterization of *Maytenus senegalensis*
750 leaf an African medicinal plant. Planta Med. 2002; 74: 1131.
- 751 87. Pistelli L, Venturi R, Marsili A, Morelli I. Alkaloids and coumarins from *Gymnosporia*
752 *senegalensis* var *spinosa* (Celastraceae). Biochem Syst Ecol. 1998; 26: 677–679.
- 753 88. Abraham DJ, Trojanek J, Munzing HP, Fong HHS, Farnsworth NR. Structure
754 elucidation of maytenoic acid, a new triterpene from *Maytenus senegalensis*
755 (Celastraceae). J Pharm Sci., 1971; 60: 1085–1087.
- 756 89. Sosa S, Morelli CF, Tubaro A, Cairolì P, Speranza G, Manitto P. Anti-inflammatory
757 activity of *Maytenus senegalensis* root extracts and of maytenoic acid. Phytomedicine.
758 2007; 14:109–114.
- 759 90. Hussein G, Miyashiro H, Nakamura N, Hattori M, Kawahata T, Otake T, Kakiuchi N,
760 Shimotohno K. Inhibitory effects of Sudanese plant extracts on HIV-1 replication and
761 HIV-1 protease. Phytother Res. 1999a; 13: 31–36.
- 762 91. Mueller M, Mechler E. Medicinal plants in tropical countries: traditional use–
763 experience–facts. Stuttgart: Thieme; 2005.
- 764 92. Muregi FW, Ishih A, Suzuki T, Kino H, Amano T, Mkoji GM, *et al.* *In vivo* antimalarial
765 activity of aqueous extracts from Kenyan medicinal plants and their chloroquine (CQ)
766 potentiation effects against a blood-induced CQ-resistant rodent parasite in mice.
767 Phytother Res. 2007; 21: 337–343.
- 768 93. Clarkson C, Maharaj VJ, Crouch NR, Grace OM, Pillay P, Matsabisa MG. *In vitro*
769 antiplasmodial activity of medicinal plants native to or naturalized in South Africa. J.
770 Ethnopharmacol. 2004; 92: 177–91.
- 771 94. Gessler MC, Nkunya MHH, Nwasumbi LB, Heinrich M, Tanner M. Screening
772 Tanzanian medicinal-plants for antimalarial activity. Acta Trop. 1994; 56: 65–77.
- 773 95. Gessler MC, Tanner M, Chollet J, Nkunya MHH, Heinrich M. Tanzanian medicinal-
774 plants used traditionally for the treatment of malaria-*in vivo* antimalarial and *in vitro*
775 cytotoxic activities. Phytother Res. 1995; 9: 504–508.
- 776 96. El-Tahir A, Satti GMH, Khalid SA. Antiplasmodial activity of selected Sudanese
777 medicinal plants with emphasis on *Maytenus senegalensis* (Lam) Exell. J
778 Ethnopharmacol. 1999; 64: 227–233.
- 779 97. Malebo HM, Tanja W, Cal M, Swaleh SA, Omolo MO, Hassanali A, Séquin U,
780 Hamburger M, Brun R, Ndiege IO. Antiplasmodial, antitrypanosomal, antileishmanial
781 and cytotoxicity activity of selected Tanzanian medicinal plants. Tan J Hlth Res. 2009;
782 11(4): 226–234.
- 783 98. Lindsey KL, Budesinsky M, Kohout L, van Staden J. Antibacterial activity of maytenoic
784 acid isolated from the root-bark of *Maytenus senegalensis*. S Afri J Bot. 2006; 72:
785 473–477.

- 786 99. da Silva G, Taniça M, Rocha J, Serrano R, Gomes ET, Sepodes B, Silva O. *In vivo*
787 anti-inflammatory effect and toxicological screening of *Maytenus heterophylla* and
788 *Maytenus senegalensis* extracts. Hum Exp Toxicol. 2010; 30(7): 693–700.
- 789 100. Hussein G, Nakamura N, Meselhy MR, Hattori M. Phenolics from *Maytenus*
790 *senegalensis*. Phytochemistry.1999b; 50: 689–694.
- 791 101. Tin-Wa M, Farnsworth NR, Fong HHS, Blomster RN, Trojanek J, Abraham DJ,
792 Persinos GJ, Dokosi OB. Biological and phytochemical evaluation of plants. IX.
793 Antitumor activity of *Maytenus senegalensis* (Celastraceae) and a preliminary
794 phytochemical investigation. Lloydia. 1971; 34: 79–87.
- 795 102. Mann A. Survey of Ethnomedicine for the treatment of Tuberculosis: Chemistry
796 Perspective. Ayanwola Printing Works, Minna, Niger State, Nigeria, 117pp; 2007.
- 797 103. Ragavan B, Krishnakumari S. Antidiabetic effect of *T. arjuna* bark extract in alloxan
798 induced diabetic rats. Indian J Clin Biochem.2006; 21: 123–128.
- 799 104. Kamalakkanan N, Prince PSM. Hypoglycaemic effect of water extracts of *Aegle*
800 *marmelos* fruits in streptozotocin-diabetic rats. J Ethnopharmacol. 2003; 87: 207–210.
- 801 105. Pari L, Venkateswaran S. Effect of an aqueous extract of *Phaseolus vulgaris* on the
802 properties of tail tendon collagen of rats with streptozotocin-induced diabetes.
803 Brazilian J Med Biol Res. 2003; 36: 861-870.
- 804 106. Rogers CB, Abbot ATD, Van-Wyk AE. A convenient thin layer chromatographic
805 technique for chemotaxonomic application in *Maytenus*. S Afri J Bot. 1999; 65: 174–
806 176.
- 807 107. Adams RP. Identification of Essential Oil Components by Gas Chromatography/
808 Quadrupole Mass spectroscopy. Allured Publishing Corporation, Carol Stream, Illinois,
809 USA; 2007.
- 810 108. Orishadipe AT, Okogun JI, Mishelia E. Gas chromatography - mass spectrometry
811 analysis of the hexane extract of *Calliandra portoricensis* and its antimicrobial activity.
812 Afri J Pure and Appl Chem. 2010; 4(7): 131–134.
- 813 109. Stein S, Mirokhin D, Tchekhovskoi D, Mallard G. The NIST Mass Spectral Search
814 Program for the NIST/EPA/NIH Mass Spectra Library. Standard Reference Data
815 Program of the National Institute of Standards and Technology. Gaithers-burg, MD,
816 US; 2002.
- 817 110. Miura T, Koike T, Ishida T. Antidiabetic activity of green tea (*Thea sinensis* L.) in
818 genetically Type 2 diabetic mice. J Hlth Sci. 2005; 51: 708–710.
- 819 111. Oubre AY, Carlson TJ, King SR, Reaven GM. From plant to patient: an ethnomedical
820 approach to the identification of new drugs for the treatment of NIDDM. Diabetologia.
821 1997; 40: 614–617.
- 822
- 823
- 824